Modality.AI

We are excited to share that Baylor College of Medicine in Houston, TX, has officially joined our Global Natural History Study as a new site dedicated to advancing ALS research. This study aims to generate the most comprehensive collection of longitudinal biofluid samples and data from at least 800 ALS and 200 healthy control cases. The study includes a collection of biofluids such as blood, urine, and cerebrospinal fluid (CSF), speech and respiratory data, and detailed clinical, demographic, and environmental information to better understand the progression of ALS and drive breakthroughs in diagnosis and treatment. Baylor College of Medicine stands out with its uniquely diverse population. "The demographics of patients served reflects our diverse community here in Houston, Texas, with 52.3% of patients reporting as Hispanic, 22.5% African American, 17.9% Caucasian, and 7.3% Asian or other," says Dr. Lydia Jane Sharp, a Principal Investigator (PI) at Baylor College of Medicine. Target ALS’ commitment to enhancing global diversity in ALS research provides invaluable insights into our understanding of the disease biology. In addition to its ethnically and racially diverse patient base, Baylor serves a large veteran population, a group known to have higher rates of ALS compared to the general public. As Dr. James Orengo, one of the PIs at Baylor, explains, “Veterans have unique environmental exposures, including intense physical training and hazardous materials. It’s unclear how these factors contribute to developing ALS, but their increased incidence offers a unique opportunity to explore the role of environmental factors.” This new partnership is a major step forward in our mission to accelerate ALS research. By working with Baylor and other global sites, we aim to uncover new insights that will benefit those living with ALS, regardless of their background. Read more on our Global Natural History Study: https://bit.ly/3YENiKv #EveryoneLives #ALSResearch #DiversityInResearch #VeteransHealth

NOV 13-15th: Join us for our 7th Annual ALS Research Symposium! Come gather with us from afar (held via Zoom so that anyone can attend easily from anywhere in the world), for our highly anticipated 3-day annual conference & listen in on presentations & talks from many of the world’s most prominent leaders in ALS research. On DAY 1 (11/13), 12 renowned ALS keynote speakers will give talks on important ALS topics including: The current clinical trials landscape, Innovation in trial design, New approaches to understanding sporadic ALS, miRNA’s, Somatic mosaicism, IPSCs modeling, the ALS exposome, subclassification, using neurofilament in clinical trials, ALS risk factors, outcome measures, ALL ALS, & more, from these esteemed researchers: Sabrina Paganoni, MD, PhD, Jeremy Shefner, MD, PhD, FAAN, Melanie Quintana, PhD, James Berry, MD, MPH, Jaime Raymond, MPH, Stephanie Melillo Fradette, PharmD, Ammar Al-Chalabi, PhD, Eran Hornstein, PhD, Justin Ichida, PhD, Eva Feldman, MD, PhD, Zinan Zhou, PhD, Dame Pamela Shaw, MD, FAAN, along w/moderators, Dr.’s Sabrina Paganoni and Robert Brown. On DAY 2 (11/14), presentations will be given from 19 members of the ALS pharma industry about current trials for which they are currently working or have recently completed towards effective treatments for ALS. We’ll hear from Acelot, Aclipse Therapeutics, Amylyx Pharmaceuticals, Arbor Technologies, Axoltis Pharma, Eikonizo Therapeutics, Kadimastem Ltd., Leal Therapeutics, Mitochon Pharmaceuticals, Inc., Modality.AI, Neurizon, NeuroSense Therapeutics, OrphAI Therapeutics, PLL Therapeutics, Prilenia, Spinogenix, Inc., Transposon Therapeutics, Inc., uniQure, Zydus Group Lifesciences. Day 2 will be moderated by James Berry, MD, MPH, and Fernando Vieira, MD. On DAY 3 (11/15), Indu Navar & EverythingALS, along with Leigh Hochberg, MD, PhD from The Ctr for Neurotech & Neuro-Recovery at MGH will converse with industry leaders from renowned companies including Compass AI, Critical Path Institute (C-Path), MGH, MIT, Passio AI, Regeneron, Microsoft, Modality, Temple University, and more. The focus will be on sharing the effects & outcomes of the transformative power of collaboration between tech companies, pharmaceutical giants, and academic institutions. Explore how AI & neurotechnology are driving innovation & accelerating the development of new treatments and technologies for ALS. With immense gratitude to our Symposium Sponsors: Mitsubishi Tanabe Pharma America, Amylyx Pharmaceuticals, Biogen, Sanofi, Spinogenix, Inc., and QurAlis. This conference would not be possible without your generosity! All are welcome & reg is free but required at https://lnkd.in/gi2yUywH . #ALS #ALSResearchSymposium #ALSconference #ALSGlobalSymposium #ALSVirtualSymposium #AllAreWelcome #ALSONEResearchSymposium #RegisterForFree

🗓️ Mark your calendars for Tuesday, October 29, at 12:00 PM ET during #BioFuture2024 for the panel discussion, "Tech Innovations of the Future: Deep Tech and AI will Impact Every Aspect of Healthcare."    Moderated by Beth Rogozinski, CEO of Oncoustics, this session will explore how #AI and #Deeptech are set to revolutionize nearly every area of healthcare—from predicting pandemics to enabling point-of-care diagnostics, remote patient monitoring, and enhancing drug discovery. The panel will focus on the current and emerging technologies reshaping #healthcare and their expected impacts on incumbents and the entire healthcare ecosystem. Panelists include:  🔹 Vinona Bhatia MD MPH, Founder, P4CI Partnering for Cancer Innovation  🔹 Remo Moomiaie-Qajar M.D., President & CEO, Cytonus Therapeutics.  🔹 Georgia Ravitz, Partner, FDA & Healthcare Regulatory, Orrick, Herrington & Sutcliffe LLP   🔗 Reserve your seat now: https://lnkd.in/gm7cvWsE   🗓️ View the full agenda here: https://lnkd.in/gQV2zSbF Join hundreds of global thought leaders at BioFuture™ 2024 from October 28-30 at Cure. in #NYC. Connect with venture capitalists, strategic investors, and key players in pharma and biotech to discover what’s next in healthcare innovation. 👉 Learn more about BioFuture here: https://lnkd.in/gVVHpGfe  #BioFuture #Biotech #HealthcareInnovation #AI #DrugDiscovery #TechBio #HealthcareInnovation #Therapeutics #DigitalHealth #DemyColton